DBV Technologies (DBVT) Company Report

DBV Technologies announced the completion of the last patient visit in its Phase 3 VITESSE clinical trial for the VIASKIN® Peanut patch in peanut-allergic children aged 4-7 years.
The company remains on track to announce topline data from the VITESSE trial in the fourth quarter of this year.
The VITESSE Phase 3 trial is currently the largest treatment intervention study in peanut allergy, evaluating the VIASKIN® Peanut patch in 654 subjects across 86 sites globally.

Nov 12, 2025, 4:50 AM

DBV Technologies to Participate in ACAAI 2025 Annual Scientific Meeting and Provide Clinical Updates

DBVT

New Projects/Investments

DBV Technologies will participate in the ACAAI 2025 Annual Scientific Meeting from November 6-10, 2025, in Orlando, Florida.
The company will host a Product Theater on November 8, 2025, to discuss a planned Phase 2 clinical study assessing the VIASKIN® Peanut patch in peanut-allergic infants aged 6-12 months.
Additionally, end-of-study results from the EPOPEX study on the long-term efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers will be presented on November 8, 2025.
DBV Technologies has a line-of-sight to a potential BLA filing for the VIASKIN® Peanut patch for toddlers (1-3 years) in the second half of next year (2026) under an Accelerated Approval Pathway.

Oct 30, 2025, 7:00 AM

DBV Technologies Reports Q3 2025 Financial Results and Raises Going Concern Doubt

DBVT

Earnings

Profit Warning

DBV Technologies reported a net loss of $102.1 million for the nine months ended September 30, 2025, with a net loss per share of ($0.82).
The company closed the third quarter of 2025 with cash and cash equivalents of $69.8 million.
Significant financing activities included $125.5 million from a private placement received on April 7, 2025, and an additional $30 million from an ATM Program received on October 6, 2025.
Despite recent financing, the company estimates its cash runway extends into the third quarter of 2026, but this is not sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

Oct 28, 2025, 9:40 PM

DBV Technologies Reports Third Quarter 2025 Financial Results

DBVT

Earnings

Profit Warning

New Projects/Investments

DBV Technologies closed Q3 2025 with a cash and cash equivalents balance of $69.8 million, providing a cash runway into the third quarter of 2026.
The company reported a net loss of $33.2 million for the three months ended September 30, 2025, and a net loss of $102.1 million for the nine months ended September 30, 2025.
Operating expenses for the nine months ended September 30, 2025, increased to $107.0 million from $96.4 million in the prior year, primarily due to increased Research & Development costs.
Despite recent financing activities, including a $125.5 million private placement and $30 million from an ATM Program, the company's cash and cash equivalents are not sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

Oct 28, 2025, 8:25 PM

DBV Technologies updates bylaws and approves executive compensation at AGM

DBVT

Executive Compensation

Share Buyback

Proxy Vote Outcomes

At the June 11, 2025 AGM, shareholders approved 2024 ex-post compensation for CEO Daniel Tassé of $348,000 in variable pay plus a $150,000 exceptional bonus, and granted exceptional bonuses of $67,454.70 to CFO Virginie Boucinha and $113,557 to CMO Pharis Mohideen.
The Company’s bylaws were amended effective immediately to allow the Board to decide by written consultation (Article 11) and to set the Board Chair age limit at 80 years (Article 13).
Share capital is confirmed at €13,697,369.70, comprising 136,973,697 fully paid ordinary shares with a par value of €0.10 each.
The AGM also approved the 2024 financial statements, renewed directors, authorized a share buyback program, and delegated to the Board various powers for capital increases and warrant issuances.

Jun 11, 2025, 12:00 AM

DBV Technologies Announces Financing and FDA Agreement for Viaskin Peanut Patch

DBVT

New Projects/Investments

Product Launch

FDA Alignment: DBV Technologies secured an FDA agreement confirming that safety data from its ongoing Phase III studies will suffice for the BLA filing for children 4 to 7—eliminating an extra 6‐month safety study and accelerating submission to H1 2026.
Robust Financing Round: The company announced a financing round of up to $306.9 million, with $125.5 million received upfront and a potential additional $181.4 million upon warrant exercisability to support independent BLA submissions for toddlers and children 4 to 7.
Share Capital Increase: DBV is executing a share capital increase by issuing new shares with attached warrants (ABSA and PFW-BS-PFW), targeting net proceeds of €106.3 million and potential gross proceeds of up to €284.5 million if all warrants are exercised.
Use of Proceeds: The funds will support working capital, advance development of the Viaskin Peanut patch, and finance preparation for a Biologics License Application and potential US commercial launch.

Mar 31, 2025, 12:00 AM

DBV Technologies Secures FDA Agreement for Viaskin BLA Filing

DBVT

Product Launch

New Projects/Investments

FDA accepts the safety exposure data from the VITESSE Phase 3 trial and its Open Label Extension for the Viaskin peanut patch in 4‑7-year-olds, eliminating the need for the COMFORT Children supplemental study.
BLA submission for the Viaskin peanut patch is now expected in the first half of 2026, potentially accelerating product launch by about one year, alongside the announcement of unaudited 2024 financial results.

Mar 24, 2025, 12:00 AM

Earnings Transcripts

Quarterly earnings call transcripts for DBV Technologies.